Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

The GlaxoSmithKline and Celgene-backed immunotherapy developer has revealed its intention to float on the Nasdaq Global Market.

The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.

The pharmaceutical firm co-led a series A equity and crossover financing round for the life sciences tool provider that will fund Chinese expansion.

Lilly Asia Ventures has returned to back the immuno-oncology therapy developer’s latest round, eight months after participating in the company’s series B.

Shionogi has joined subsidiaries of Merck Group and Amgen in the equity portion of a series D round for the digital therapeutics developer.

Asahi Kasei, GlaxoSmithKline and Johnson & Johnson helped the respiratory disease drug developer boost its overall funding to $150m.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Bascom Palmer Eye Institute’s spinout is working on AR/VR vision diagnosis and augmentation technology and has secured more cash five months after its seed funding.

IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.